Consun Pharmaceutical Group Limited 

$1.7800
40
+$0.00+0%Monday 13:51

Statistics

Day High
1.78
Day Low
1.78
52W High
1.8
52W Low
1.12
Volume
115
Avg. Volume
7
Mkt Cap
1.5B
P/E Ratio
8.9
Dividend Yield
5.59%
Dividend
0.1

Upcoming

Dividends

5.59%Dividend Yield
Oct 2026
$0.05
Jun 2026
$0.05
Sep 2025
$0.04
Jun 2025
$0.04
Sep 2024
$0.04
10Y Growth
18.52%
5Y Growth
20.83%
3Y Growth
20.04%
1Y Growth
23.29%

Earnings

Aug 26Expected
Q1 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
0.53
0.62
0.71
0.81
Expected EPS
N/A
Actual EPS
0.8076146324400001

Financials

31.54%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
483.22MRevenue
152.43MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CPHGF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sanofi
SNY
Mkt Cap112.71B
Sanofi operates in the pharmaceutical sector, offering a wide range of medicines and vaccines, directly competing with Consun Pharmaceutical's product offerings.
Pfizer
PFE
Mkt Cap167.52B
Pfizer is a global biopharmaceutical company that develops and manufactures drugs and vaccines, including in areas where Consun Pharmaceutical is active.
Novartis
NVS
Mkt Cap307B
Novartis is a multinational pharmaceutical company that produces drugs in many of the same therapeutic areas as Consun Pharmaceutical, making it a direct competitor.
Merck
MRK
Mkt Cap361.73B
Merck & Co., Inc. is a leading global biopharmaceutical company that competes with Consun Pharmaceutical in developing medicines for various diseases.
GSK
GSK
Mkt Cap100.88B
GlaxoSmithKline is a global healthcare company that researches and develops a broad range of pharmaceutical products, competing with Consun Pharmaceutical in multiple areas.
Abbvie
ABBV
Mkt Cap514.92B
AbbVie is a biopharmaceutical company that has a competitive portfolio of drugs, directly competing with Consun Pharmaceutical in several therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap664.95B
Johnson & Johnson is a diversified healthcare giant that manufactures pharmaceuticals across a broad range of areas, competing with Consun Pharmaceutical.
Bristol-Myers Squibb
BMY
Mkt Cap127.02B
Bristol Myers Squibb is a global biopharmaceutical company with a focus on discovering, developing, and delivering innovative medicines that compete with Consun Pharmaceutical.
Astrazeneca
AZN
Mkt Cap289.14B
AstraZeneca is a global, science-led biopharmaceutical business that competes in developing and commercializing prescription medicines in areas overlapping with Consun Pharmaceutical.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a leader in research-focused healthcare with strengths in pharmaceuticals and diagnostics, competing in areas relevant to Consun Pharmaceutical's interests.

About

Consun Pharmaceutical Group Limited operates as an investment holding company, primarily engaged in the research, development, manufacturing, and distribution of traditional Chinese medicines and sophisticated medical contrast agents throughout the People's Republic of China. The company's operations are structured into two main divisions: Consun Pharmaceutical and Yulin Pharmaceutical. Consun offers a diverse array of pharmaceutical products. For kidney-related conditions, it provides uremic clearance granule for chronic kidney diseases and Yishen Huashi particles to address proteinuria. In the field of medical imaging, the company supplies Gadopentetate Dimeglumine injections, a contrast medium vital for MRI diagnostics of the central nervous system, abdomen, chest, pelvis, and extremities, alongside assessing renal function. Another key imaging agent is Iopamidol injections, utilized in neuroradiology, angiography, and urography. Its extensive portfolio of traditional Chinese medicines includes Zhixueling capsules, effective in managing various bleeding disorders such as uterine bleeding, prolonged lochia, intermenstrual spotting, post-contraceptive ring bleeding, hemorrhoidal bleeding, and epistaxis. Gyn Antidysmenorrheic tablets are offered to alleviate irregular and painful menstruation, including issues experienced during perimenopause due to hepatic depression and blood deficiency. For feminine hygiene, Antibacterial Fujie lotion combats common vaginal infections caused by Staphylococcus aureus, Candida albicans, and Escherichia coli. The company also markets bone-setting liquid and Yunxiang analgesic tincture for a range of ailments including rheumatism, common colds, headaches, stomachaches, chest pain, gastric pain, and chilblains. Additionally, Sanqi Chuangchun capsules are available to enhance blood circulation and reduce stasis, while Shiduqing capsules, tablets, and Paeonol ointment target various skin conditions. The product line is further rounded out with hepatobiliary, gastroenterology, tonic, and other general medicines. Beyond its traditional Chinese remedies and contrast media, the company also markets pharmaceutical products such as Yuanli Kang, an iron-dextrin oral solution; Yibao Yua, an erythromycin estolate suspension; and Yuantong Ning, a cetirizine hydrochloride oral solution. Established in 1997, Consun Pharmaceutical Group Limited is headquartered in Guangzhou, People's Republic of China.
Show More
CEO
Meng An
Employees
2847
Country
Cayman Islands
ISIN
KYG2524A1031
WKN
000A1XAEC

Listings

0 Comments

Share your thoughts

FAQs

What is Consun Pharmaceutical Group Limited stock price today?▼
The current price of CPHGF is $1.78 USD — it has increased by +0% in the past 24 hours. Watch Consun Pharmaceutical Group Limited stock price performance more closely on the chart.
What is Consun Pharmaceutical Group Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Consun Pharmaceutical Group Limited stocks are traded under the ticker CPHGF.
What is Consun Pharmaceutical Group Limited market cap?▼
Today Consun Pharmaceutical Group Limited has the market capitalization of 1.5B
When is the next Consun Pharmaceutical Group Limited earnings date?▼
Consun Pharmaceutical Group Limited is going to release the next earnings report on March 24, 2027.
What were Consun Pharmaceutical Group Limited earnings last quarter?▼
CPHGF earnings for the last quarter are 0.1 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Consun Pharmaceutical Group Limited revenue for the last year?▼
Consun Pharmaceutical Group Limited revenue for the last year amounts to 483.22M USD.
What is Consun Pharmaceutical Group Limited net income for the last year?▼
CPHGF net income for the last year is 152.43M USD.
Does Consun Pharmaceutical Group Limited pay dividends?▼
Yes, CPHGF dividends are paid semi-annual. The last dividend per share was 0.05 . As of today, Dividend Yield (FWD)% is 5.59%.
How many employees does Consun Pharmaceutical Group Limited have?▼
As of November 14, 2026, the company has 2,847 employees.
In which sector is Consun Pharmaceutical Group Limited located?▼
Consun Pharmaceutical Group Limited operates in the Health & Wellness sector.
When did Consun Pharmaceutical Group Limited complete a stock split?▼
Consun Pharmaceutical Group Limited has not had any recent stock splits.
Where is Consun Pharmaceutical Group Limited headquartered?▼
Consun Pharmaceutical Group Limited is headquartered in Guangzhou, Cayman Islands.